Charles River Laboratories International Inc. has launched its eXpDNA plasmid platform, established from the company’s contract development and manufacturing (CDMO) and biologics testing experience.
 
The platform significantly reduces plasmid development and production timelines while streamlining the development journey for cell and gene therapy and vaccine developers with a focus on product quality and consistency.
 
The platform leverages Charles River’s expertise in developing, manufacturing, and releasing more than 200 High Quality (HQ) and Good Manufacturing Practice- (GMP) compliant plasmid DNA batches. eXpDNA supports a client’s plasmid DNA strategy by offering a proven and standardized plasmid platform approach, suitable for plasmid DNA programs across various applications.
 
The platform consists of an efficient and robust a plug-n-play screening toolbox for tackling challenging plasmids, phase-appropriate production with fit-for-purpose facilities, on-hand materials, and in-house analytics. The standardized process approach expedites batch turnaround times to five weeks for HQ plasmid and 10 weeks for GMP plasmid.
 
Committed to supporting a large array of advanced therapy clients this universal platform has been adopted successfully for multiple plasmid-based cell and gene therapeutics and vaccines, accommodating various plasmid types.
 
Charles River will officially launch the eXpDNA platform during Phacilitate Advanced Therapies Week, happening January 17 – 20, 2023 at the Miami Beach Convention Center in Miami, FL.